Contraception and Family Planning Practice Questions

Q: A patient was placed on depot medroxy progesterone acetate. She now complains of irregular spotting. Which of the following is NOT a treatment option?

Place a progestin-only implant.. **Explanation:** The primary side effect of Depot Medroxyprogesterone Acetate (DMPA) is **breakthrough bleeding or irregular spotting**, caused by the thinning of the endometrial lining (endometrial atrophy) and increased fragility of the capillaries due to the lack of estrogen. **Why Option D is the Correct Answer:** Placing a **progestin-only implant** (like Nexplanon) is **not** a treatment for DMPA-induced spotting. In fact, it would likely exacerbate the problem. The underlying cause of spotting in DMPA users is a "progestin-only" environment leading to an unstable, atrophic endometrium. Adding more progestin does not stabilize the lining; instead, it further suppresses endogenous estrogen, worsening the irregular bleeding. **Why the other options are incorrect (Management of Spotting):** * **Option A (COCPs):** Combined Oral Contraceptive Pills provide ethinyl estradiol, which helps stabilize the endometrium and promote organized growth, effectively stopping the spotting. * **Option B (Mefenamic Acid):** NSAIDs are a first-line non-hormonal treatment. They work by inhibiting prostaglandin synthesis, which reduces local inflammation and decreases menstrual blood flow. * **Option C (Premarin):** Premarin (conjugated equine estrogen) provides exogenous estrogen to "rescue" the atrophic endometrium, promoting healing and stabilization of the lining. **High-Yield Clinical Pearls for NEET-PG:** * **DMPA Schedule:** 150 mg intramuscularly every 3 months (12 weeks). * **Amenorrhea:** After 1 year of DMPA use, approximately 50-70% of women develop amenorrhea, which is a normal and expected effect. * **Bone Mineral Density (BMD):** Long-term DMPA use is associated with a reversible decrease in BMD (FDA Black Box Warning). * **Weight Gain:** DMPA is the only contraceptive significantly associated with weight gain.

Q: Nonoxynol-9 is a/an:

Barrier contraceptive. **Explanation:** **Nonoxynol-9** is a non-ionic surfactant that acts as a **chemical barrier contraceptive (spermicide)**. It works by disrupting the cell membrane of the spermatozoa, leading to loss of motility and eventual death of the sperm before they can enter the cervical canal. It is commonly available in the form of foams, jellies, creams, and films, or as a coating on condoms and diaphragms. **Analysis of Options:** * **Option A (Hormonal):** Incorrect. Nonoxynol-9 contains no hormones (like Estrogen or Progesterone) and does not interfere with the Hypothalamic-Pituitary-Ovarian axis or ovulation. * **Option B (Intrauterine):** Incorrect. While some medicated IUDs exist (Copper or Levonorgestrel), Nonoxynol-9 is a topical agent applied vaginally, not an intrauterine device. * **Option D (Post-coital):** Incorrect. Spermicides must be applied **before** intercourse to be effective. Post-coital (emergency) contraception typically involves high-dose progestins (Levonorgestrel) or SPRMs (Ulipristal). **Clinical Pearls for NEET-PG:** * **Failure Rate:** When used alone, spermicides have a high failure rate (Typical use: ~28%). They are most effective when used in combination with mechanical barriers like a diaphragm. * **STI Risk:** Contrary to older beliefs, Nonoxynol-9 **does not protect against HIV/STIs**. In fact, frequent use can cause vaginal and rectal irritation/ulceration, which may actually **increase** the risk of HIV transmission. * **Mechanism:** It reduces the surface tension of the sperm midpiece and tail, causing irreversible immobilization.

Q: Which of the following statements about misoprostol is true?

It is used for first-trimester abortion.. **Explanation:** **Misoprostol** is a synthetic **Prostaglandin E1 (PGE1)** analog, widely used in obstetrics due to its potent uterotonic and cervical ripening properties. **Why Option B is correct:** Misoprostol is a cornerstone in medical termination of pregnancy (MTP). For **first-trimester abortion** (up to 9 weeks/63 days), it is used in combination with Mifepristone (Progesterone antagonist). Mifepristone sensitizes the myocardium and softens the cervix, while Misoprostol (administered 24–48 hours later) induces uterine contractions to expel the products of conception. **Analysis of Incorrect Options:** * **Option A:** Misoprostol is a **PGE1** analog. **Dinoprostone** is the PGE2 analog used for induction of labor. * **Option C & D:** While these statements are clinically "true" in practice (Misoprostol is used for PPH and can be given rectally), they are considered **secondary or off-label** compared to the primary, FDA-approved indication in the context of standard NEET-PG questioning. For PPH, Oxytocin remains the first-line drug of choice. Misoprostol is used as an adjunct (usually 800 mcg). * **Note on Route:** Misoprostol can be administered via oral, sublingual, vaginal, and rectal routes. Sublingual has the fastest onset, while vaginal has the highest bioavailability. **High-Yield Clinical Pearls for NEET-PG:** * **Dose for MTP:** 400 mcg (oral/vaginal) following 200 mg Mifepristone. * **Dose for PPH Prophylaxis:** 600 mcg orally (AMTSL). * **Dose for PPH Treatment:** 800 mcg sublingually/rectally. * **Side Effects:** Shivering and pyrexia (most common), transient diarrhea. * **Contraindication:** Previous LSCS (increased risk of uterine rupture when used for induction of labor in the 3rd trimester).

Q: What is the most common complication following intrauterine device insertion?

Bleeding. **Explanation:** The most common complication and the most frequent reason for the discontinuation of an Intrauterine Device (IUD), specifically the Copper-T, is **Bleeding (Option A)**. This typically manifests as menorrhagia (increased menstrual flow), metrorrhagia (intermenstrual spotting), or polymenorrhea. The underlying mechanism involves a local inflammatory response in the endometrium, leading to increased vascularity, capillary permeability, and local fibrinolytic activity. **Analysis of Incorrect Options:** * **B. Pain:** This is the second most common complication. It usually occurs as spasmodic dysmenorrhea due to uterine contractions attempting to expel the foreign body. While common, its incidence is lower than bleeding. * **C. Pelvic Infection:** While IUDs slightly increase the risk of Pelvic Inflammatory Disease (PID) within the first 20 days post-insertion (due to the introduction of vaginal flora into the uterus), it is not the most common complication. * **D. Uterine Perforation:** This is a rare but serious iatrogenic complication, occurring in approximately 1 per 1,000 insertions. It most commonly happens during the procedure itself. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of removal:** Bleeding and Pain. * **Most common side effect of LNG-IUS (Mirena):** Amenorrhea or oligomenorrhea (unlike Copper-T, which causes bleeding). * **Ideal time for insertion:** During menstruation or within 10 days of the cycle (to ensure the patient is not pregnant and the cervix is slightly dilated). * **Protective effect:** IUDs are known to be protective against endometrial cancer.

Q: The use of a levonorgestrel-releasing intrauterine contraceptive device is helpful in all of the following conditions except:

Premenstrual symptoms. **Explanation:** The **Levonorgestrel-releasing Intrauterine System (LNG-IUS)**, such as Mirena, works primarily by releasing 20 mcg of levonorgestrel daily directly into the uterine cavity. This causes profound endometrial atrophy and thickening of cervical mucus. **Why "Premenstrual Symptoms" is the correct answer:** Premenstrual Syndrome (PMS) is driven by cyclical hormonal fluctuations (estrogen and progesterone) during the luteal phase of the **ovarian cycle**. Since the LNG-IUS acts locally and does not consistently suppress ovulation, the systemic hormonal shifts responsible for PMS remain largely unaffected. Therefore, it is not a primary treatment for premenstrual symptoms. **Analysis of other options:** * **Menorrhagia:** The LNG-IUS is the "medical gold standard" for idiopathic menorrhagia. It causes thinning of the endometrial lining, leading to a 90% reduction in menstrual blood loss and often resulting in amenorrhea. * **Dysmenorrhea:** By reducing endometrial prostaglandins and decreasing menstrual flow, it significantly alleviates both primary and secondary dysmenorrhea (especially that associated with adenomyosis). * **Pelvic Inflammatory Disease (PID):** The progestogen thickens the cervical mucus, creating a biological barrier that prevents the ascent of pathogens into the upper genital tract, thereby exerting a protective effect against PID. **High-Yield Clinical Pearls for NEET-PG:** * **Life span:** 5 years (Mirena) or 7 years (recent updates). * **Non-contraceptive uses:** First-line for Adenomyosis, Endometrial Hyperplasia (without atypia), and as the progestogen component of Hormone Replacement Therapy (HRT). * **Most common side effect:** Irregular spotting/bleeding during the first 3–6 months. * **Pearl:** Unlike Copper-T, LNG-IUS *decreases* the risk of PID and ectopic pregnancy (though if pregnancy occurs, the *proportion* of ectopics is higher).

Q: Which of the following is NOT a method used for laparoscopic sterilization?

Irving method. **Explanation:** The **Irving method** is the correct answer because it is an **open surgical technique** for tubal ligation, not a laparoscopic one. In this procedure, the fallopian tube is cut, and the proximal end is buried into the posterior wall of the uterus, while the distal end is buried in the broad ligament. Due to the extensive tissue mobilization and suturing required, it cannot be performed via a laparoscope. It is known for having the lowest failure rate among all sterilization techniques. **Analysis of other options:** * **Electrocoagulation (Option A):** This was one of the earliest laparoscopic methods. It uses unipolar or bipolar current to thermally destroy a segment of the fallopian tube. * **Falope Ring (Option B):** Also known as the Yoon ring, this is a silastic band applied laparoscopically using a special applicator. It creates a loop of the tube, causing ischemia and eventual fibrosis. * **Filshie Clip (Option D):** This is a titanium clip lined with silicone rubber. It is applied laparoscopically to crush a 3-5 mm segment of the tube. It is popular due to minimal tissue destruction and higher potential for reversibility compared to other methods. **High-Yield Clinical Pearls for NEET-PG:** * **Most common laparoscopic method:** Falope ring (widely used in mass sterilization camps). * **Method with lowest failure rate:** Irving method (Failure rate ~1 in 1,000). * **Method with highest failure rate:** Madlener method (no longer recommended). * **Pomeroy’s Method:** The most common "open" method used during postpartum sterilization (minilap) due to its simplicity and efficacy. * **Bipolar Cautery:** Preferred over unipolar cautery in laparoscopy to prevent accidental bowel burns.

Q: Which intrauterine contraceptive device (IUCD) is associated with the highest incidence of ectopic pregnancy?

Progestasert. **Explanation:** The correct answer is **Progestasert**. **1. Why Progestasert is the correct answer:** Progestasert is a first-generation hormone-releasing IUCD that releases progesterone. While all IUCDs significantly reduce the *absolute* risk of all pregnancies (including ectopic), if a pregnancy does occur with an IUCD in situ, the *relative* risk of it being ectopic is higher. Progestasert carries the highest risk among all IUCDs because progesterone **decreases fallopian tube motility** and slows down ciliary action. This delay in the transport of the fertilized ovum through the tube increases the likelihood of implantation within the tube rather than the uterus. **2. Why the other options are incorrect:** * **Lippes loop (Option B):** A non-medicated (inert) IUCD. While it has a higher failure rate than medicated IUCDs, it does not specifically alter tubal motility to the extent that hormonal devices do. * **Copper-T and Multiload (Options C & D):** These are medicated copper-releasing IUCDs. Copper acts primarily as a spermicide and causes a sterile inflammatory response in the endometrium. While they can be associated with ectopic pregnancy if they fail, the risk is significantly lower than with progesterone-only devices. **High-Yield Clinical Pearls for NEET-PG:** * **Highest Ectopic Risk:** Progestasert (Progesterone-releasing). * **Lowest Ectopic Risk:** LNG-20 (Mirena) actually has a lower absolute risk of ectopic pregnancy compared to women using no contraception, because it is highly effective at preventing conception altogether. * **Mechanism:** Progesterone = Decreased tubal motility; Copper = Spermicidal/Inflammatory. * **Most Common Site of Ectopic Pregnancy:** Ampulla of the Fallopian tube. * **Key Fact:** The most common cause of ectopic pregnancy overall is Pelvic Inflammatory Disease (PID), but among IUCD failures, Progestasert carries the highest relative risk.

Question 1

A patient was placed on depot medroxy progesterone acetate. She now complains of irregular spotting. Which of the following is NOT a treatment option?

Accepted Answer

Place a progestin-only implant.

Answer

Add combined oral contraceptive pills for 4 weeks.

Answer

Give mefenamic acid for 1 week.

Answer

Give premarin for 4 weeks.

Question 2

A 28-year-old female, with a one-year-old daughter, diagnosed with diabetes a few months ago which is controlled with diet and exercise, presents seeking contraception. Which of the following is the best contraceptive method of choice for this patient?

Accepted Answer

Condoms used by the husband

Answer

Intrauterine contraceptive device (IUCD)

Answer

Oral contraceptive pills (OCP)

Answer

Vaginal sponge

Question 3

Nonoxynol-9 is a/an:

Accepted Answer

Barrier contraceptive

Answer

Hormonal contraceptive

Answer

Intrauterine contraceptive

Answer

Post-coital contraceptive

Question 4

What is the most common infection associated with IUCD use?

Accepted Answer

Chlamydia

Answer

Staphylococcus epidermidis

Answer

Staphylococcus aureus

Answer

Group D Streptococcus

Question 5

If a patient misses oral contraceptive pills for 10 consecutive days, what is the most appropriate management?

Accepted Answer

Continue the pills and use an additional form of contraception

Answer

Stop the pills and resume after 7 days

Answer

Continue the pills as usual

Answer

Take an additional pill

Question 6

Which of the following statements about misoprostol is true?

Accepted Answer

It is used for first-trimester abortion.

Answer

It is a PGE2 analog.

Answer

It is used in the management of postpartum hemorrhage (PPH).

Answer

It is administered rectally.

Question 7

What is the most common complication following intrauterine device insertion?

Accepted Answer

Bleeding

Answer

Pain

Answer

Pelvic infection

Answer

Uterine perforation

Question 8

The use of a levonorgestrel-releasing intrauterine contraceptive device is helpful in all of the following conditions except:

Accepted Answer

Premenstrual symptoms

Answer

Menorrhagia

Answer

Dysmenorrhea

Answer

Pelvic inflammatory disease

Question 9

Which of the following is NOT a method used for laparoscopic sterilization?

Accepted Answer

Irving method

Answer

Electrocoagulation

Answer

Falope ring

Answer

Filchie clip

Question 10

Which intrauterine contraceptive device (IUCD) is associated with the highest incidence of ectopic pregnancy?

Accepted Answer

Progestasert

Answer

Lippes loop

Answer

Copper-T

Answer

Multiload device

Contraception and Family Planning — MCQs

Contraception and Family Planning — MCQs

On this page

Practice by Chapter

Want unlimited practice?